Can I give Wegovy (semaglutide) to a 16-year-old who is overweight but not obese for a two-month course?

No, you should not give Wegovy to a 16-year-old who is overweight but not obese for only 2 months

The Endocrine Society explicitly recommends against using obesity medications in adolescents who are overweight but not obese, except in the context of clinical trials 1. This is a strong recommendation that directly addresses your scenario.

Why This Is Not Appropriate

Wrong Patient Population

• Wegovy is FDA-approved only for adolescents aged 12+ with obesity (BMI ≥95th percentile), not those who are merely overweight 2
• The FDA label specifically states it's for "pediatric patients aged 12 years and older with obesity" - your patient doesn't meet this criterion
• The pivotal STEP TEENS trial enrolled adolescents with obesity (BMI ≥95th percentile) or overweight with weight-related comorbidities - "all but one of the participants had obesity" 3

Wrong Treatment Duration

• Two months is far too short - the medication requires at least 12 weeks at full dosage to assess efficacy 1
• The STEP TEENS trial ran for 68 weeks (over 16 months), not 2 months 3
• Semaglutide has a half-life of approximately 1 week and takes 4-5 weeks to reach steady state 2
• Stopping after 2 months would likely result in weight regain, as the medication doesn't provide lasting metabolic changes in such a short timeframe

Missing Prerequisites

The guidelines are clear that pharmacotherapy should only be considered when 1:

1. A formal program of intensive lifestyle modification has failed to limit weight gain or ameliorate comorbidities
2. Treatment must be combined with a concomitant lifestyle modification program of the highest intensity available
3. Only clinicians experienced in the use of antiobesity agents should prescribe these medications

What You Should Do Instead

For a 16-year-old who is overweight (but not obese):

1. Implement intensive lifestyle modification first - this is the evidence-based first-line approach 1
2. Address behavioral factors: screen for sugar-sweetened beverage intake, screen time, sleep patterns, and psychosocial issues 1
3. Provide family-based intervention with structured programs involving diet, physical activity, and behavioral counseling
4. Monitor for progression to obesity or development of weight-related comorbidities

Critical Safety Considerations

Even if this patient were obese, a 2-month course would be problematic because:

• Gastrointestinal side effects are common (62% in the STEP TEENS trial) and typically occur during dose escalation 3
• Cholelithiasis risk: 4% of adolescents in the semaglutide group developed gallstones 3
• Long-term safety data in adolescents is limited to 68 weeks 4
• The medication requires careful monitoring that wouldn't be adequately captured in 2 months

Bottom Line

This scenario violates multiple evidence-based principles: wrong patient population (overweight vs. obese), wrong duration (2 months vs. minimum 12 weeks to assess response, ideally much longer), and likely missing the prerequisite of failed intensive lifestyle modification. Focus on intensive lifestyle intervention as the appropriate evidence-based approach for this patient 1.